# AltPep

> AltPep is a Seattle biotech company spun out of the University of Washington that is building both diagnostic tests and disease-modifying drugs for amyloid diseases such as Alzheimer's and Parkinson's. Its work is anchored on the alpha-sheet, a non-standard protein structure discovered by founder and CEO Valerie Daggett, which forms in the toxic soluble oligomers that appear at the earliest, pre-symptomatic stages of disease. AltPep's SOBA blood test aims to flag those toxic oligomers years before symptoms, while its SOBIN peptide therapeutics are designed to neutralize them.

- **Founded:** 2019
- **Headquarters:** Seattle, Washington, United States
- **Founders:** Valerie Daggett (Founder & CEO)
- **Team size:** ~33 employees
- **Products:** SOBA (Soluble Oligomer Binding Assay), SOBIN (Soluble Oligomer Binding INhibitor), Alpha-sheet platform
- **Notable:** FDA Breakthrough Device designation for SOBA-AD blood test (March 2022), SOBA-AD distinguished Alzheimer's patients from controls with 100% sensitivity, >95% specificity, >98% AUC in a Nature Scientific Reports study, Raised over $120 million across Series A, additional financing and Series B

## Products & services

- **SOBA (Soluble Oligomer Binding Assay)** — A blood-based diagnostic platform that detects toxic alpha-sheet oligomers. The lead test, SOBA-AD, received FDA Breakthrough Device designation and, in a Nature Scientific Reports study, distinguished Alzheimer's patients from cognitively unimpaired subjects with 100% sensitivity, >95% specificity and >98% area under the curve.
- **SOBIN (Soluble Oligomer Binding INhibitor)** — A class of custom-designed synthetic peptide therapeutics engineered to bind and neutralize toxic oligomers. Lead programs SOBIN-AD and SOBIN-PD target Alzheimer's and Parkinson's disease and are being advanced toward Phase 1 clinical trials.
- **Alpha-sheet platform** — The underlying discovery and design engine - a non-standard protein structure (alpha-sheet) that appears in toxic oligomers early in amyloid disease, used to rationally design both detection and therapeutic peptides across multiple amyloid conditions.

## Achievements

- FDA Breakthrough Device designation for SOBA-AD blood test (March 2022)
- SOBA-AD distinguished Alzheimer's patients from controls with 100% sensitivity, >95% specificity, >98% AUC in a Nature Scientific Reports study
- Raised over $120 million across Series A, additional financing and Series B
- GeekWire 2023 Health Innovation of the Year Award
- Spun out of decades of alpha-sheet research in Valerie Daggett's UW lab

## Latest updates

- **2025-11** — Presented preclinical SOBIN-AD therapeutic data at major Alzheimer's conferences (CTAD/AAIC).
- **2024-04** — Study published in Nature's Scientific Reports further affirming the SOBA-AD blood test's potential to detect Alzheimer's.
- **2023-06** — Closed $52.9M Series B led by Senator Investment Group with Section 32, Partners Investment and Eli Lilly to push SOBIN therapeutics toward Phase 1.
- **2022-12** — Published blood-test results showing detection of toxic amyloid oligomers years before symptoms.
- **2022-03** — Received FDA Breakthrough Device designation for SOBA-AD.

## Links

- Website: https://altpep.com
- LinkedIn: http://www.linkedin.com/company/altpep
- Twitter/X: https://twitter.com/altpepcorp

---

Profile page: https://yespress.io/altpep
Published by YesPress — https://yespress.io
Last updated: 2026-06-16